Xtandi Archives - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

Biogen Inc., a US biotechnology company, has got marketing authorisation from the European medicines regulator for its drug to treat neurodegenerative disease, amyotrophic lateral sclerosis.

UK approves oral pill to treat advanced prostate cancer

HQ Team July 19, 2024: A new pill that treats hormone sensitive advance prostate cancer has been approved by the National Institute for.

by HealthQuill
July 19, 2024
0 Comments

The Food and Drug Administration (FDA) has green-lighted Astellas Pharma’s prostrate cancer drug Xtandi five weeks ahead of the scheduled approval date.

Drugs Health Pharma

Astellas’ prostate cancer drug for metastasis-free survival gets nod

HQ Team November 18, 2023: The Food and Drug Administration (FDA) has green-lighted Astellas Pharma’s prostrate cancer drug Xtandi five weeks ahead of.

by HealthQuill
November 18, 2023
0 Comments

The USFDA has approved Pfizer Inc’s oral Talzenna drug in combination with Xtandi to treat advanced prostate cancer in adult patients, according to a statement.

Drugs Health Pharma

Pfizer gets FDA nod for combination drug to treat advanced prostate cancer

HQ Team June 21, 2023: The USFDA has approved Pfizer Inc’s oral Talzenna drug in combination with Xtandi to treat advanced prostate cancer.

by HealthQuill
June 20, 2023
0 Comments